RM-048 (Revolution Medicines)

RM-048 (Revolution Medicines): sourced facts only. name: "Here, we describe RM-048, a potent, selective, and oral tri-complex inhibitor of KRASG12V(ON)." [DOI:10.1158/1535-7163.targ-23-b137]; target: "Here, we describe RM-048, a potent, selective, and oral tri-complex inhibitor of KRASG12V(ON)." [DOI:10.1158/1535-7163.targ-23-b137]; developer: "1Revolution Medicines, Inc, Redwood City, CA," [DOI:10.1158/1535-7163.targ-23-b137]; modality: "Developing a selective inhibitor of KRASG12V presents significant drug discovery challenges." [DOI:10.1158/1535-7163.targ-23-b137]; stage: "Repeated daily oral administration of RM-048 was well tolerated and demonstrated profound anti-tumor activity, driving tumor regressions across a panel of KRASG12V xenograft models, including NSCLC, PDAC, and CRC models." [DOI:10.1158/1535-7163.targ-23-b137]